---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-016793"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:37:50.745615+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ZyVersa Q1 2023 net loss $3.5M; cash only $1.3M, needs financing

## Summary
- Cash of $1.3M as of March 31, 2023, sufficient only on month-to-month basis; company requires additional financing.
- Net loss of $3.5M for Q1 2023 improved $0.2M vs Q1 2022 net loss of $3.7M, aided by $1.0M deferred tax benefit.
- G&A expenses rose 53.7% to $3.5M due to insurance, marketing, and PIPE failure payments.
- VAR 200 investigator-initiated trial expected Q4 2023; IND submission for IC 100 anticipated Q2 2024.

## SEC filing metadata
- accession: 0001493152-23-016793
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315223016793/0001493152-23-016793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315223016793/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-016793
- JSON: https://secwatch.observer/filing/0001493152-23-016793.json
- Plain text: https://secwatch.observer/filing/0001493152-23-016793.txt

## Key facts
- Earnings Releases
  ZyVersa Therapeutics, Inc. reported the first quarter of 2023 ending March 31, 2023 results: net income approximately $3.5 million.
  - Period: the first quarter of 2023 ending March 31, 2023
  - Net income: approximately $3.5 million
  - Result: reported results
  source text: Net losses were approximately $3.5 million for the three months ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1859007/000149315223016793/0001493152-23-016793-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.